DaVita (DVA) Stock Forecast, Price Target & Predictions
DVA Stock Forecast
DaVita stock forecast is as follows: an average price target of $145.00 (represents a -1.74% downside from DVA’s last price of $147.57) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
DVA Price Target
The average price target for DaVita (DVA) is $145.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $145.00 to $145.00. This represents a potential -1.74% downside from DVA's last price of $147.57.
DVA Analyst Ratings
According to 3 Wall Street analysts, DaVita's rating consensus is 'Hold'. The analyst rating breakdown for DVA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
DaVita Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 07, 2024 | Kevin Fischbeck | Bank of America Securities | $145.00 | $133.53 | 8.59% | -1.74% |
| May 06, 2024 | Andrew Mok | Barclays | $150.00 | $134.45 | 11.57% | 1.65% |
| Oct 31, 2022 | Sarah James | Barclays | $81.00 | $70.54 | 14.83% | -45.11% |
| Aug 19, 2022 | Andrew Mok | UBS | $117.00 | $93.10 | 25.67% | -20.72% |
| Jun 28, 2022 | David MacDonald | Truist Financial | $90.00 | $79.44 | 13.29% | -39.01% |
The latest DaVita stock forecast, released on Aug 07, 2024 by Kevin Fischbeck from Bank of America Securities, set a price target of $145.00, which represents a 8.59% increase from the stock price at the time of the forecast ($133.53), and a -1.74% decrease from DVA last price ($147.57).
DaVita Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $147.50 |
| Last Closing Price | $147.57 | $147.57 | $147.57 |
| Upside/Downside | -100.00% | -100.00% | -0.05% |
In the current month, the average price target of DaVita stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to DaVita's last price of $147.57. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 06, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jan 05, 2023 | CFRA | Hold | Upgrade | |
| Aug 19, 2022 | UBS | Buy | Upgrade | |
| Jun 28, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
DaVita's last stock rating was published by Barclays on May 06, 2024. The company gave DVA a "Equal-Weight" rating, the same as its previous rate.
DaVita Financial Forecast
DaVita Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.12B | $3.00B | $2.87B | $2.92B | $2.95B | $2.93B | $2.82B | $2.94B | $2.94B | $2.92B | $2.82B | $2.91B | $2.92B | $2.88B | $2.84B | $2.90B | $2.90B |
| Avg Forecast | $3.39B | $3.48B | $3.39B | $3.30B | $3.38B | $3.37B | $3.29B | $3.20B | $3.27B | $3.25B | $3.15B | $3.03B | $3.01B | $3.02B | $2.95B | $2.84B | $2.93B | $2.98B | $2.93B | $2.89B | $2.91B | $2.91B | $2.87B | $2.84B | $2.93B | $2.94B | $2.93B | $2.84B | $2.92B | $2.85B |
| High Forecast | $3.43B | $3.51B | $3.43B | $3.34B | $3.41B | $3.40B | $3.32B | $3.22B | $3.29B | $3.25B | $3.15B | $3.03B | $3.04B | $3.04B | $2.98B | $2.87B | $2.96B | $2.98B | $2.93B | $2.89B | $2.91B | $2.91B | $2.87B | $2.84B | $2.93B | $2.94B | $2.93B | $2.84B | $2.92B | $2.85B |
| Low Forecast | $3.36B | $3.45B | $3.36B | $3.27B | $3.35B | $3.34B | $3.26B | $3.18B | $3.26B | $3.25B | $3.15B | $3.03B | $2.99B | $3.00B | $2.92B | $2.81B | $2.90B | $2.98B | $2.93B | $2.89B | $2.91B | $2.91B | $2.87B | $2.84B | $2.93B | $2.94B | $2.93B | $2.84B | $2.92B | $2.85B |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.01% | 1.00% | 0.99% | 1.00% | 0.98% | 1.01% | 1.01% | 1.02% | 0.99% | 0.99% | 1.00% | 0.98% | 1.00% | 0.99% | 1.02% |
DaVita's average Quarter revenue forecast for Dec 23 based on 4 analysts is $3.01B, with a low forecast of $2.99B, and a high forecast of $3.04B. DVA's average Quarter revenue forecast represents a -3.62% decrease compared to the company's last Quarter revenue of $3.12B (Sep 23).
DaVita EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $664.71M | $590.34M | $493.47M | $442.52M | $501.30M | $602.61M | $509.47M | $561.79M | $637.75M | $675.35M | $609.47M | $549.33M | $599.96M | $593.09M | $612.76M | $632.54M | $623.39M |
| Avg Forecast | $670.95M | $688.26M | $671.43M | $653.52M | $667.89M | $665.89M | $651.05M | $633.30M | $646.05M | $642.28M | $623.40M | $642.08M | $594.98M | $597.12M | $583.82M | $583.71M | $482.61M | $595.52M | $587.06M | $530.64M | $582.95M | $582.57M | $573.98M | $472.95M | $585.55M | $587.57M | $585.36M | $433.76M | $584.42M | $570.10M |
| High Forecast | $677.46M | $694.94M | $677.94M | $659.86M | $674.37M | $672.35M | $657.37M | $637.27M | $650.03M | $642.52M | $623.40M | $770.49M | $600.93M | $601.65M | $589.48M | $700.45M | $579.14M | $595.52M | $587.06M | $636.77M | $582.95M | $582.57M | $573.98M | $567.53M | $585.55M | $587.57M | $585.36M | $520.51M | $584.42M | $570.10M |
| Low Forecast | $664.72M | $681.87M | $665.19M | $647.45M | $661.69M | $659.70M | $645.01M | $629.33M | $644.06M | $642.05M | $623.40M | $513.66M | $591.01M | $593.75M | $578.40M | $466.97M | $386.09M | $595.52M | $587.06M | $424.51M | $582.95M | $582.57M | $573.98M | $378.36M | $585.55M | $587.57M | $585.36M | $347.01M | $584.42M | $570.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.11% | 1.01% | 0.85% | 0.92% | 0.84% | 1.03% | 0.96% | 0.96% | 1.09% | 1.18% | 1.29% | 0.94% | 1.02% | 1.01% | 1.41% | 1.08% | 1.09% |
4 analysts predict DVA's average Quarter EBITDA for Dec 23 to be $594.98M, with a high of $600.93M and a low of $591.01M. This is -10.49% lower than DaVita's previous annual EBITDA (Sep 23) of $664.71M.
DaVita Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $246.63M | $178.69M | $170.67M | $113.16M | $164.69M | $224.81M | $162.12M | $249.43M | $259.75M | $293.82M | $237.40M | $254.00M | $217.54M | $201.60M | $239.59M | $244.87M | $143.27M |
| Avg Forecast | $281.51M | $365.13M | $327.69M | $258.79M | $218.19M | $284.98M | $253.09M | $207.01M | $183.93M | $233.68M | $222.34M | $223.44M | $139.83M | $172.56M | $146.46M | $203.13M | $181.02M | $157.10M | $185.80M | $184.66M | $160.04M | $200.58M | $193.40M | $202.18M | $166.00M | $128.04M | $117.74M | $180.92M | $147.99M | $110.47M |
| High Forecast | $285.07M | $369.74M | $331.83M | $262.05M | $220.94M | $288.57M | $256.29M | $209.62M | $192.26M | $234.61M | $222.36M | $268.13M | $152.63M | $188.79M | $148.31M | $243.76M | $217.22M | $157.10M | $185.80M | $221.60M | $164.15M | $200.58M | $193.40M | $242.62M | $166.00M | $128.04M | $117.74M | $217.10M | $147.99M | $110.47M |
| Low Forecast | $278.12M | $360.72M | $323.74M | $255.66M | $215.56M | $281.54M | $250.04M | $204.51M | $175.61M | $232.75M | $222.32M | $178.75M | $123.38M | $158.04M | $144.69M | $162.50M | $144.81M | $157.10M | $185.80M | $147.73M | $155.93M | $200.58M | $193.40M | $161.75M | $166.00M | $128.04M | $117.74M | $144.73M | $147.99M | $110.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.43% | 1.22% | 0.84% | 0.63% | 1.05% | 1.21% | 0.88% | 1.56% | 1.29% | 1.52% | 1.17% | 1.53% | 1.70% | 1.71% | 1.32% | 1.65% | 1.30% |
DaVita's average Quarter net income forecast for Dec 23 is $139.83M, with a range of $123.38M to $152.63M. DVA's average Quarter net income forecast represents a -43.30% decrease compared to the company's last Quarter net income of $246.63M (Sep 23).
DaVita SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $376.88M | $364.02M | $331.61M | $379.71M | $365.45M | $315.22M | $294.82M | $322.72M | $293.10M | $298.09M | $281.43M | $304.52M | $363.28M | $316.21M | $263.58M | $278.43M | $298.74M |
| Avg Forecast | $370.38M | $379.94M | $370.64M | $360.76M | $368.69M | $367.58M | $359.40M | $349.60M | $356.64M | $354.55M | $344.13M | $406.33M | $328.44M | $329.62M | $322.28M | $369.39M | $311.61M | $325.04M | $320.42M | $335.81M | $318.18M | $317.97M | $313.28M | $239.68M | $319.60M | $320.70M | $319.49M | $199.03M | $318.98M | $311.16M |
| High Forecast | $373.97M | $383.63M | $374.24M | $364.26M | $372.27M | $371.15M | $362.88M | $351.79M | $358.83M | $354.68M | $344.13M | $487.60M | $331.73M | $332.13M | $325.41M | $443.27M | $373.93M | $325.04M | $320.42M | $402.97M | $318.18M | $317.97M | $313.28M | $287.61M | $319.60M | $320.70M | $319.49M | $238.83M | $318.98M | $311.16M |
| Low Forecast | $366.94M | $376.41M | $367.20M | $357.41M | $365.27M | $364.17M | $356.06M | $347.41M | $355.54M | $354.43M | $344.13M | $325.07M | $326.25M | $327.76M | $319.29M | $295.51M | $249.29M | $325.04M | $320.42M | $268.65M | $318.18M | $317.97M | $313.28M | $191.74M | $319.60M | $320.70M | $319.49M | $159.22M | $318.98M | $311.16M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.14% | 1.13% | 0.90% | 1.22% | 1.12% | 0.98% | 0.88% | 1.01% | 0.92% | 0.95% | 1.17% | 0.95% | 1.13% | 0.99% | 1.32% | 0.87% | 0.96% |
DaVita's average Quarter SG&A projection for Dec 23 is $328.44M, based on 4 Wall Street analysts, with a range of $326.25M to $331.73M. The forecast indicates a -12.85% fall compared to DVA last annual SG&A of $376.88M (Sep 23).
DaVita EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 1 | 2 | 2 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.70 | $1.96 | $1.89 | $1.26 | $1.81 | $2.38 | $1.68 | $2.47 | $2.48 | $2.76 | $2.18 | $2.27 | $1.80 | $1.65 | $1.92 | $1.89 | $1.38 |
| Avg Forecast | $3.28 | $4.26 | $3.82 | $3.02 | $2.54 | $3.32 | $2.95 | $2.41 | $2.14 | $2.72 | $2.59 | $1.95 | $1.63 | $2.01 | $1.71 | $1.18 | $0.93 | $1.77 | $2.09 | $1.87 | $1.80 | $2.25 | $2.17 | $1.79 | $1.87 | $1.44 | $1.32 | $1.48 | $1.66 | $1.24 |
| High Forecast | $3.32 | $4.31 | $3.87 | $3.05 | $2.58 | $3.36 | $2.99 | $2.44 | $2.24 | $2.73 | $2.59 | $1.95 | $1.78 | $2.20 | $1.73 | $1.19 | $0.95 | $1.77 | $2.09 | $1.87 | $1.85 | $2.25 | $2.17 | $1.79 | $1.87 | $1.44 | $1.32 | $1.48 | $1.66 | $1.24 |
| Low Forecast | $3.24 | $4.20 | $3.77 | $2.98 | $2.51 | $3.28 | $2.91 | $2.38 | $2.05 | $2.71 | $2.59 | $1.95 | $1.44 | $1.84 | $1.69 | $1.16 | $0.92 | $1.77 | $2.09 | $1.87 | $1.75 | $2.25 | $2.17 | $1.79 | $1.87 | $1.44 | $1.32 | $1.48 | $1.66 | $1.24 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.34% | 1.15% | 1.61% | 1.35% | 1.02% | 1.14% | 0.90% | 1.37% | 1.10% | 1.27% | 1.22% | 1.22% | 1.25% | 1.25% | 1.30% | 1.14% | 1.11% |
According to 4 Wall Street analysts, DaVita's projected average Quarter EPS for Dec 23 is $1.63, with a low estimate of $1.44 and a high estimate of $1.78. This represents a -39.63% decrease compared to DVA previous annual EPS of $2.70 (Sep 23).
DaVita Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AMN | AMN Healthcare Services | $24.47 | $51.00 | 108.42% | Buy |
| ACHC | Acadia Healthcare Company | $39.64 | $81.50 | 105.60% | Buy |
| AMED | Amedisys | $85.37 | $143.38 | 67.95% | Hold |
| SGRY | Surgery Partners | $21.03 | $35.00 | 66.43% | Buy |
| CYH | Community Health Systems | $3.21 | $5.00 | 55.76% | Buy |
| HCA | HCA Healthcare | $307.78 | $423.20 | 37.50% | Buy |
| UHS | Universal Health Services | $182.60 | $249.67 | 36.73% | Hold |
| THC | Tenet Healthcare | $132.55 | $161.50 | 21.84% | Buy |
| OPCH | Option Care Health | $23.42 | $27.33 | 16.70% | Buy |
| ENSG | Ensign Group | $140.00 | $159.00 | 13.57% | Buy |
| EHC | Encompass Health | $96.94 | $107.50 | 10.89% | Buy |
| DVA | DaVita | $147.57 | $145.00 | -1.74% | Hold |